AVP
In the context of the launch of its Late Stage Fund, AVP continues to strengthen its leadership team to reinforce its global platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502656787/en/
(Photo: Business Wire)
First, after the recruitment of Elizabeth de Saint-Aignan in the USA, Warda's appointment in Europe completes the senior team of the new AVP Late Stage Fund.
Prior to joining AVP, Warda Shaheen held the position of Director at OMERS Growth Equity, where she conducted investments in prominent software companies such as Coveo, TouchBistro, PandaDoc, Clio, Celigo and GitLab. Previously, Warda worked in public markets at CPP Investments where she ran a $500M public markets portfolio in the thematic investing team. She also worked at Point72 Asset Management, Bain & Company and Deutsche Bank. Warda has experience working in the United States, Canada, United Kingdom, Singapore, Hong Kong and Germany. Warda holds an MSc in Financial Economics from the University of Oxford, a BESc in Mechanical Engineering from the University of Western University and an HBA in Business Administration the Richard Ivey School of Business.
Second, Pedro's appointment as Partner in charge of investor relations underlines AVP's objective of managing more capital for top tier institutional investors. Pedro brings extensive experience in fundraising of technology funds, from his tenure at Target Global, where he played a key role in fundraising multiple tech funds and fostering investor relationships. He has also held senior positions at MVision and Hamilton Lane. Having started his career in the venture capital arm of FINEP, the Brazilian innovation agency, Pedro holds an MBA and a BSc in Industrial Engineering from Pontifícia Universidade Católica do Rio de Janeiro.
“On behalf of the AVP team, I am delighted to extend a warm welcome to Warda and Pedro as our newest Partners. I am also very proud that AVP can attract such talents, and in the case of Warda, convince top tier investor in the North American market to come to Paris. Warda will play a key role in developing our new Late Stage Fund strategy, focusing on Europe. With this new Late Stage fund, we now have the capability to support entrepreneurs throughout their journey, from the early stages to IPO, as well as post-IPO, which sets us apart in the market. Warda brings extensive knowledge and a proven track record in investing in Late Stage companies in the US and in Europe. In the context of our platform expansion and ongoing fundraising efforts across various strategies, we are very happy to benefit from Pedro’s substantial fundraising experience of technology focused fund. His background at Target Global will undoubtedly add value to the entire AVP platform. At AVP, nothing is more important than the quality, the diversity and the complementarity of the team. Since 8 years, we have welcomed 9 Partners and are now ready to further expand the team with these two talents. No doubt that they will play a key role in the next chapter of our journey," commented François Robinet, Managing Partner at AVP.
“I am thrilled to become a part of the outstanding team of investors at AVP. Since I was introduced to the firm, I recognized this platform had the vision, skills, and leadership to amplify the global landscape of technology investing with a diverse partnership that leverages expertise across the financing spectrum. AVP's Late Stage strategy in Europe addresses several challenges in the European ecosystem, including the shortage of local funding for exceptional European technology leaders to expand globally. At AVP, we look forward to bringing our collective knowledge to support such leaders at various stages in both the private and public markets,” commented Warda Shaheen, General Partner at AVP.
“I am excited to join an incredibly talented team of investor at AVP. I have been fortunate to follow the development of the platform over the years and, now as part of the team, look forward to develop their robust capital base to attract additional top tier institutional investors globally,” commented Pedro Barros, Partner at AVP.
About AVP (AXA Venture Partners)
AVP (AXA Venture Partners) is a global venture capital firm specializing in high-growth, technology- enabled companies, managing more than $2 billion in assets across four investment strategies: Venture, Growth, Late Stage, and Fund of Funds. Since its establishment in 2016, AVP has invested in more than 60 technology companies in Venture and Growth stages in the US and Europe.
With offices in New York, London, and Paris, AVP supports companies in expanding internationally and provides portfolio companies with tailored business development opportunities to further accelerate their growth. AVP operates under AXA IM- Alts, the alternative investment business unit of AXA IM.
For more information, visit axavp.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502656787/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom